World

The ESG case for the Oxford / AstraZeneca vaccine

[ad_1] This is a guest post from Steven Desmyter, Man Group’s Co-Chief Investment Officer, argues that when it comes to the Covid-19 vaccine, it’s worth not benefiting from the disaster. The markets seem to have decided that Pfizer and Moderna are the winners of the COVID-19 vaccine race. While readings …

Read More »